Valuation: VACY AS

Market Cap 891M 0 92.57M 81.13M 75.01M 69.13M 130M 8.92B 132M 896M 351M 4.36B 348M 340M 15.07B P/E 2026 *
-4.22x
P/E 2027 * -29.5x
Enterprise Value 406M 0 42.2M 36.98M 34.19M 31.51M 59.09M 4.06B 60.24M 408M 160M 1.99B 159M 155M 6.87B EV / Sales 2026 *
-
EV / Sales 2027 * 1.94x
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 2018-12-31
President 49 2016-12-31
Director of Finance/CFO 51 2021-05-02
Director TitleAgeSince
Director/Board Member 54 -
Director/Board Member 57 -
Chairman 45 2025-04-22
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 93.28M
+0.88%+0.08%+54.51%+58.77% 53.79B
+1.80%+5.16%+53.09%+86.95% 54.69B
+1.50%-0.48%+5.91%+410.19% 23.2B
+0.18%+2.51%-16.08%-14.29% 23.31B
+1.46%+4.02%+35.97%-4.03% 20.03B
+0.30%-2.68%+30.50%-33.10% 17.31B
0.00%-6.00%+163.95%+284.69% 14.99B
+1.49%+1.49%+31.63%+654.98% 15.36B
+1.06%+0.14%+26.20%+182.44% 13.96B
Average +0.87%-1.84%+42.85%+180.73% 26.29B
Weighted average by Cap. +1.09%-1.78%+42.92%+140.83%

Financials

2026 *2027 *
Net sales - 162M 0 16.79M 14.72M 13.61M 12.54M 23.51M 1.62B 23.97M 162M 63.71M 791M 63.1M 61.73M 2.73B
Net income -208M -0 -21.59M -18.92M -17.49M -16.12M -30.23M -2.08B -30.82M -209M -81.91M -1.02B -81.12M -79.37M -3.52B -41.58M -0 -4.32M -3.78M -3.5M -3.22M -6.05M -416M -6.16M -41.78M -16.38M -203M -16.22M -15.87M -703M
Net Debt -485M -0 -50.37M -44.15M -40.82M -37.62M -70.53M -4.85B -71.91M -487M -191M -2.37B -189M -185M -8.2B -578M -0 -59.97M -52.55M -48.59M -44.78M -83.97M -5.78B -85.61M -580M -228M -2.83B -225M -220M -9.77B
Logo VACY AS
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.730NOK
Average target price
5.000NOK
Spread / Average Target
+83.15%

Quarterly revenue - Rate of surprise